Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpatientstagecelladjuvant
  Phrases that lowered it: asthmahealthalcoholopenhistory
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 10.3% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 82 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 146 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 83.7% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 507 (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer NCT00738673 · started 2008 · scored riskier than 71% of active trials completed
• A Study of Degarelix in Patients With Prostate Cancer NCT00928434 · started 2009 · scored riskier than 61% of active trials completed
• Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients NCT00884273 · started 2009 · scored riskier than 28% of active trials completed
• Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer NCT00801242 · started 2008 · scored riskier than 34% of active trials completed
• Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer NCT00833248 · started 2009 · scored riskier than 38% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.